IN8bio, Inc. Form 8-K Summary
Reporting date: December 11, 2023. The filing reports a material financing transaction, an unregistered equity securities issuance, and related Regulation FD disclosure. IN8bio is a clinical-stage biotechnology company; this filing does not provide operating or period-end financial statements.
Financing and Key Terms
- IN8bio entered into a Securities Purchase Agreement for a private placement of 11,823,829 units at $1.22 per unit.
- Each unit consists of either one common share or one pre-funded warrant for one common share, plus one Series A warrant and one Series B warrant.
- Expected aggregate initial gross proceeds are approximately $14.4 million, before placement fees and other expenses. The company stated that the proceeds are expected to fund operations into 2025; the filing does not provide clear net proceeds or a detailed use-of-proceeds budget.
- Cantor Fitzgerald & Co. acted as sole placement agent. Closing was subject to customary conditions and was expected on or about December 13, 2023.
- Pre-funded warrants have a $0.0001 exercise price, are immediately exercisable, and remain exercisable until fully exercised.
- Series A warrants have a $1.25 exercise price, are immediately exercisable, and expire 18 months after issuance.
- Series B warrants have a $1.50 exercise price, are immediately exercisable, and expire five years after issuance.
- Warrant exercises are subject to beneficial ownership limitations generally set at 4.99%, with the ability to increase or decrease the limit by notice up to 19.99%.
Registration Rights and Contingencies
- IN8bio agreed to register the resale of the issued shares and shares underlying the warrants.
- The registration statement is due within 30 days after closing. The company agreed to seek effectiveness within 30 days after filing, or within 60 days if reviewed by the SEC.
- If specified filing, effectiveness, or availability deadlines are missed, the company may owe liquidated damages of 1% of each investor’s invested amount per 30-day period, subject to a contractual cap.
- The private placement was structured as an unregistered transaction exempt from registration under Section 4(a)(2) of the Securities Act.
Clinical-Data-Linked Warrant Features
- IN8bio may require exercise of the Series A warrants at $1.25 per share if it publicly announces specified INB-100 clinical data for the ten currently enrolled patients, subject to survival, evaluability, minimum follow-up, stock-price, and trading-volume conditions.
- IN8bio may redeem Series B warrants for $0.01 per warrant after announcing specified INB-100 data for all enrolled patients covering at least 22 months, also subject to stock-price and trading-volume conditions. Holders may exercise at $1.50 per share before redemption.
Financial Metrics and Changes Versus Prior Period
- Liquidity: The financing is expected to provide approximately $14.4 million of gross capital and fund operations into 2025, according to management.
- Revenue, profit, cash flow, margins, debt, and cash balance: The filing does not provide clear values for these metrics.
- Material change: The principal reported change is the planned issuance of common stock or pre-funded warrants and additional warrants, creating potential immediate and future dilution. The filing does not quantify the resulting percentage dilution.
Investor Verification Points
- Confirm that the private placement closed and determine the final mix of common shares and pre-funded warrants issued.
- Verify gross-to-net proceeds after placement fees and expenses and compare the proceeds with the company’s cash runway and projected spending.
- Assess the potential dilution from the 11,823,829 base securities and the Series A, Series B, and pre-funded warrants.
- Review the full warrant agreements for adjustment provisions, redemption conditions, and ownership limitations.
- Track INB-100 clinical-data announcements and the related conditions that could trigger mandatory exercise or Series B warrant redemption.
- Confirm timely filing and effectiveness of the resale registration statement and monitor any liquidated-damages exposure.